NSEI:JBCHEPHARM

Stock Analysis Report

J. B. Chemicals & Pharmaceuticals

Executive Summary

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and APIs in India and internationally.

Snowflake

Fundamentals

Flawless balance sheet with solid track record and pays a dividend.

Share Price & News

How has J. B. Chemicals & Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.5%

JBCHEPHARM

1.4%

IN Pharmaceuticals

1.4%

IN Market


1 Year Return

19.7%

JBCHEPHARM

-20.0%

IN Pharmaceuticals

2.3%

IN Market

Return vs Industry: JBCHEPHARM exceeded the Indian Pharmaceuticals industry which returned -20% over the past year.

Return vs Market: JBCHEPHARM exceeded the Indian Market which returned 2.3% over the past year.


Shareholder returns

JBCHEPHARMIndustryMarket
7 Day0.5%1.4%1.4%
30 Day-8.4%-7.1%2.7%
90 Day-3.2%-5.2%-1.4%
1 Year21.3%19.7%-19.3%-20.0%4.3%2.3%
3 Year-3.9%-6.1%-27.3%-28.8%20.9%14.9%
5 Year78.5%62.8%-11.9%-14.6%41.2%28.2%

Price Volatility Vs. Market

How volatile is J. B. Chemicals & Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is J. B. Chemicals & Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

3.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: JBCHEPHARM (₹359.25) is trading below our estimate of fair value (₹370.35)

Significantly Undervalued: JBCHEPHARM is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: JBCHEPHARM is good value based on its PE Ratio (13.7x) compared to the Pharmaceuticals industry average (15.6x).

PE vs Market: JBCHEPHARM is poor value based on its PE Ratio (13.7x) compared to the Indian market (13x).


Price to Earnings Growth Ratio

Low PEG Ratio: JBCHEPHARM is poor value based on its PEG Ratio (1x)


Price to Book Ratio

PB vs Industry: JBCHEPHARM is overvalued based on its PB Ratio (1.9x) compared to the IN Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is J. B. Chemicals & Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

13.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: JBCHEPHARM's forecast earnings growth (13.6% per year) is above the savings rate (7.6%).

Earnings vs Market: JBCHEPHARM's earnings (13.6% per year) are forecast to grow slower than the Indian market (18.1% per year).

High Growth Earnings: JBCHEPHARM's earnings are forecast to grow, but not significantly.

Revenue vs Market: JBCHEPHARM's revenue (9.4% per year) is forecast to grow slower than the Indian market (11.4% per year).

High Growth Revenue: JBCHEPHARM's revenue (9.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: JBCHEPHARM's Return on Equity is forecast to be low in 3 years time (15.2%).


Next Steps

Past Performance

How has J. B. Chemicals & Pharmaceuticals performed over the past 5 years?

11.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: JBCHEPHARM's earnings have grown by 11.2% per year over the past 5 years.

Accelerating Growth: JBCHEPHARM's earnings growth over the past year (38%) exceeds its 5-year average (11.2% per year).

Earnings vs Industry: JBCHEPHARM earnings growth over the past year (38%) exceeded the Pharmaceuticals industry 14.4%.


Return on Equity

High ROE: JBCHEPHARM's Return on Equity (14.2%) is considered low.


Return on Assets

ROA vs Industry: JBCHEPHARM has a higher Return on Assets than the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: JBCHEPHARM has improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is J. B. Chemicals & Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: JBCHEPHARM's short term assets (₹10.5B) exceeds its short term liabilities (₹2.4B)

Long Term Liabilities: JBCHEPHARM's short term assets (10.5B) exceeds its long term liabilities (648.4M)


Debt to Equity History and Analysis

Debt Level: JBCHEPHARM's debt to equity ratio (1.7%) is considered satisfactory

Reducing Debt: JBCHEPHARM's debt to equity ratio has reduced from 9.9% to 1.7% over the past 5 years.

Debt Coverage: JBCHEPHARM's debt is well covered by operating cash flow (748.4%).

Interest Coverage: JBCHEPHARM earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: JBCHEPHARM has a high level of physical assets or inventory.

Debt Coverage by Assets: JBCHEPHARM's debt is covered by short term assets (assets are 40.684840x debt).


Next Steps

Dividend

What is J. B. Chemicals & Pharmaceuticals's current dividend yield, its reliability and sustainability?

1.41%

Current Dividend Yield


Dividend Yield vs Market

company1.4%marketbottom25%0.6%markettop25%2.5%industryaverage0.9%forecastin3Years1.4%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: JBCHEPHARM's dividend (1.41%) is higher than the bottom 25% of dividend payers in the Indian market (0.61%).

High Dividend: JBCHEPHARM's dividend (1.41%) is low compared to the top 25% of dividend payers in the Indian market (2.51%).

Stable Dividend: JBCHEPHARM's dividend payments have been volatile in the past 10 years.

Growing Dividend: JBCHEPHARM's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (19.4%), JBCHEPHARM's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: JBCHEPHARM's dividends in 3 years are forecast to be well covered by earnings (18.6% payout ratio).


Next Steps

Management

What is the CEO of J. B. Chemicals & Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

9.3yrs

Average board tenure


CEO

Jyotindra Mody (90yo)

0yrs

Tenure

₹64,076,000

Compensation

Mr. Jyotindra Bhagwanlal Mody serves as Chairman and Managing Director at J. B. Chemicals & Pharmaceuticals Ltd. Mr. Mody has experience of over four decades in the Indian pharmaceutical industry. Mr. Mody ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Jyotindra's total compensation is reasonable compared to companies of similar size in the Indian market.

Compensation vs Earnings: Jyotindra's compensation has increased by more than 20% in the past year.


Board Age and Tenure

9.3yrs

Average Tenure

66.5yo

Average Age

Experienced Board: JBCHEPHARM's board of directors are considered experienced (9.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Sell₹9,629,46122 Feb 19
Nitin Doshi
EntityIndividual
Shares30,186
Max Price₹319.00

Ownership Breakdown


Management Team

  • Kamlesh Udani (65yo)

    Director of Technical & Production and Executive Director

    • Tenure: 0yrs
    • Compensation: ₹18.18m
  • Sandeep Nasa

    Head of Moscow Representative Office - Marketing & Head of Russia - CIS Business

    • Tenure: 0yrs
    • Compensation: ₹23.64m
  • Shirish Mody (78yo)

    Director of Marketing & Whole-Time Director

    • Tenure: 0yrs
    • Compensation: ₹64.08m
  • Pranabh Mody (56yo)

    President

    • Tenure: 0yrs
    • Compensation: ₹28.11m
  • Jyotindra Mody (90yo)

    Chairman & MD

    • Tenure: 0yrs
    • Compensation: ₹64.08m
  • Bharat Sukhlal Mehta (71yo)

    Director of Planning & Development and Whole-Time Director

    • Tenure: 0yrs
    • Compensation: ₹28.11m
  • Pradeep Singh (55yo)

    President of Global Business

    • Tenure: 0yrs
  • Nirav Mody (38yo)

    President of Global Business & Business Development

    • Tenure: 0yrs
    • Compensation: ₹9.93m
  • Mayur Mehta

    Company Secretary & VP of Compliance

    • Tenure: 0yrs
  • Vijay Bhatt

    Chief Financial Officer

    • Tenure: 0yrs

Board Members

  • Shad Mapetla (68yo)

    Chairman of Biotech Laboratories (Pty ) Ltd

    • Tenure: 0yrs
  • Rajiv Mody (61yo)

    Non-Executive & Independent Director

    • Tenure: 14.4yrs
    • Compensation: ₹480.00k
  • Kamlesh Udani (65yo)

    Director of Technical & Production and Executive Director

    • Tenure: 0yrs
    • Compensation: ₹18.18m
  • Shirish Mody (78yo)

    Director of Marketing & Whole-Time Director

    • Tenure: 0yrs
    • Compensation: ₹64.08m
  • Pranabh Mody (56yo)

    President

    • Tenure: 0yrs
    • Compensation: ₹28.11m
  • Jyotindra Mody (90yo)

    Chairman & MD

    • Tenure: 0yrs
    • Compensation: ₹64.08m
  • Bharat Sukhlal Mehta (71yo)

    Director of Planning & Development and Whole-Time Director

    • Tenure: 0yrs
    • Compensation: ₹28.11m
  • Satyanarain Agarwala

    Independent Director

    • Tenure: 9.3yrs
    • Compensation: ₹980.00k
  • Krupa Gandhi

    Independent Director

    • Tenure: 0yrs
    • Compensation: ₹900.00k
  • Devang Shah (52yo)

    Non-Executive Independent Director

    • Tenure: 4.8yrs
    • Compensation: ₹660.00k

Company Information

J. B. Chemicals & Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: J. B. Chemicals & Pharmaceuticals Limited
  • Ticker: JBCHEPHARM
  • Exchange: NSEI
  • Founded: 1976
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹28.741b
  • Shares outstanding: 80.24m
  • Website: https://www.jbcpl.com

Location

  • J. B. Chemicals & Pharmaceuticals Limited
  • Cnergy IT Park
  • Unit A2, 3rd floor & Unit A, 8th floor
  • Mumbai
  • Maharashtra
  • 400030
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
506943BSE (Mumbai Stock Exchange)YesEquity SharesININRDec 2001
JBCHEPHARMNSEI (National Stock Exchange of India)YesEquity SharesININRDec 2001

Biography

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and APIs in India and internationally. The company manufactures a range of specialty ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 12:46
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.